Prothena Corporation plc has provided a corporate overview focusing on their efforts to deliver life-saving therapies targeting diseases caused by protein dysregulation. These efforts are directed towards conditions such as Alzheimer's disease, Parkinson's disease, and transthyretin amyloidosis. The presentation highlights the significant global impact of these diseases, including the economic burden and the number of individuals affected. Prothena showcases their biology-directed engine, which is designed to eliminate pathogenic proteins while preserving normal biology, and their extensive pipeline of clinical programs. The company has established collaborations with organizations like Bristol Myers Squibb, Novo Nordisk, and Roche to advance their therapeutic developments. You can access the full presentation through the link below.